270 related articles for article (PubMed ID: 3116031)
1. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
[TBL] [Abstract][Full Text] [Related]
2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
3. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
Chang RJ; Laufer LR; Meldrum DR; DeFazio J; Lu JK; Vale WW; Rivier JE; Judd HL
J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
[TBL] [Abstract][Full Text] [Related]
4. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
Gonzalez F; Hatala DA; Speroff L
Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
[TBL] [Abstract][Full Text] [Related]
5. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
Rittmaster RS; Thompson DL
J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
[TBL] [Abstract][Full Text] [Related]
6. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
[TBL] [Abstract][Full Text] [Related]
7. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
White D; Leigh A; Wilson C; Donaldson A; Franks S
Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
[TBL] [Abstract][Full Text] [Related]
8. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
[TBL] [Abstract][Full Text] [Related]
9. Pulsatile gonadotrophin secretion in women with polycystic ovary syndrome after gonadotrophin-releasing hormone agonist treatment.
Cheung AP; Lu JK; Chang RJ
Hum Reprod; 1997 Jun; 12(6):1156-64. PubMed ID: 9221993
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
[TBL] [Abstract][Full Text] [Related]
11. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
Judd HL; Rigg LA; Anderson DC; Yen SS
J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
[TBL] [Abstract][Full Text] [Related]
12. Specific factors predict the response to pulsatile gonadotropin-releasing hormone therapy in polycystic ovarian syndrome.
Gill S; Taylor AE; Martin KA; Welt CK; Adams JM; Hall JE
J Clin Endocrinol Metab; 2001 Jun; 86(6):2428-36. PubMed ID: 11397835
[TBL] [Abstract][Full Text] [Related]
13. GnRH analog administration in patients with polycystic ovarian disease.
Meden-Vrtovec H
Int J Gynaecol Obstet; 1995 Aug; 50(2):179-83. PubMed ID: 7589755
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
[TBL] [Abstract][Full Text] [Related]
15. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian disease.
Christman GM; Randolph JF; Kelch RP; Marshall JC
J Clin Endocrinol Metab; 1991 Jun; 72(6):1278-85. PubMed ID: 1902845
[TBL] [Abstract][Full Text] [Related]
16. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
Steingold KA; Lobo RA; Judd HL; Lu JK; Chang RJ
J Clin Endocrinol Metab; 1986 May; 62(5):1048-51. PubMed ID: 2937800
[TBL] [Abstract][Full Text] [Related]
17. Pituitary-ovarian relationships in polycystic ovary syndrome.
Baird DT; Corker CS; Davidson DW; Hunter WM; Michie EA; Van Look PF
J Clin Endocrinol Metab; 1977 Oct; 45(4):798-801. PubMed ID: 334789
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
[TBL] [Abstract][Full Text] [Related]
20. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
Apter D; Bützow T; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
